Gilead Sciences Strikes Deal with Merus for Trispecific Antibody Development

1. Gilead Sciences Inc. has entered into a strategic collaboration with Merus NV to discover novel antibody-based trispecific T-cell engagers as part of their joint efforts to advance cancer therapeutics.
2. This collaboration comes after Gilead Sciences acquired CymaBay Therapeutics for $4.3 billion earlier in the year.
3. Gilead Sciences is actively involved in developing treatments for various conditions such as solid tumors (with compounds like GS-0201), ovarian cancer, triple negative breast cancer, prostate cancer, and primary CNS malignancies.
4. The trispecific antibody discovery deal aims to leverage both companies' expertise to create innovative therapies for cancer treatment.
5. Gilead Sciences is a research-based biopharmaceutical company with a focus on discovering, developing, and commercializing medicines for various diseases, including cancer.

This collaboration between Gilead Sciences and Merus NV represents an expansion of their respective research pipelines, aiming to bring new therapeutics to patients with unmet medical needs.